Distinctive gene expression profiles characterize donor biopsies from HCV-positive kidney donors

Transplantation

Volumn 90, Issue 11, 2010, Pages 1172-1179

  Mas, Valeria R ^a,b,c   Archer, Kellie J ^a   Suh, Lacey ^a   Scian, Mariano ^a,b   Posner, Marc P ^b   Maluf, Daniel G ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Gene expression; Hepatitis C virus; Kidney transplant; Marginal donors

Indexed keywords

HEPATITIS C ANTIBODY; INTERFERON; INTERLEUKIN 8;

ADULT; APOPTOSIS; ARTICLE; CELL DEATH; CONNECTIVE TISSUE; CONTROLLED STUDY; DONOR SELECTION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT; MALE; MICROARRAY ANALYSIS; MORPHOLOGY; NATURAL KILLER CELL; PRIORITY JOURNAL;

ADULT; BIOPSY; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DELAYED GRAFT FUNCTION; DONOR SELECTION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNITY, INNATE; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RNA; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRGINIA;

EID: 78650306096     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f9ca6c     Document Type: Article

References (52)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 567.
2. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981.
3. Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: An update. Am J Kidney Dis 2003; 42: 631.
4. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3.
5. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52.
6. Tokars JI, Miller ER, Alter MJ, et al. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44: 98.
7. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004; 65: 2335.
8. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multi-centre study. Nephrol Dial Transplant 2004; 19: 904.
9. Fehr T, Ambuhl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19: 1049. USRDS, Annual Data Report. 2009.
10. Kasprzyk T, Kwiatkowski A, Wszola M, et al. Long term results of kidney transplantation from HCV-positive donors. Transplant Proc 2007; 39: 2701.
11. Fabrizi F, Bunnapradist S, Lunghi G, et al. Transplantation in kidneys from HCV-positive donors: A safe strategy? J Nephrol 2003; 16: 617.
12. Gentil MA, Rocha JL, Rodríguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455.
13. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257.
14. Batty DS Jr, Swanson SJ, Kirk AD, et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: Associated factors and patient survival. Am J Transplant 2001; 1: 179.
15. Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in waitlisted long-term dialysis patients. Am J Transplant 2004; 4: 203.
16. Fabrizi F, Messa P, Martin P. Current status of renal transplantation from HCV-positive donors. Int J Artif Organs 2009; 32: 251.
17. Mansfield ES, Sarwal MM. Arraying the orchestration of allograft pathology. Am J Transplant 2004; 4: 853.
18. Halloran PF, Einecke G. Microarrays and transcriptome analysis in renal transplantation. Nat Clin Pract Nephrol 2006; 2: 2.
19. Ying L, Sarwal M. In praise of arrays. Pediatr Nephrol 2009; 24: 1643.
20. Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 2010; 10: 1238.
21. Garcia-ValdecasasJ, BernalC, Garcia F, et al. Epidemiology ofhepatitis C virus infection in patients with renal disease. J Am Soc Nephrol 1994; 5: 186.
22. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glo-merulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465.
23. Fornasieri A, Li M, Armelloni S, et al. Glomerulonephritis induced by human IgMk-IgG cryoglobulins in mice. Lab Invest 1993; 69: 531.
24. Ayodele OE, Salako BL. Hepatitis C virus (HCV) and chronic renal disease. Afr J Med Med Sci 2003; 32: 287.
25. D'Amico G, Fornasieri A. Cryoglobulinemic glomerrulonephritis: A membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995; 25: 361.
26. Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44: 141.
27. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus infected renal allograft recipients. Transplantation 1995; 59: 1676.
28. Chan TM, Ho SK, Lai CL, et al. Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection. Nephrol Dial Transplant 1999; 14: 717.
29. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: Predictors of patient and graft survival. Transplantation 2007; 83: 853.
30. Kanto T, Hayashi N. Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Hepatol Res 2007; 37: S319.
31. O'Neill LA, Bowie AG. Sensing and signaling in antiviral innate immunity. Curr Biol 2010; 20: R328.
32. Radkowski M, Gallegos-Orozco J, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106.
33. Ballardini G, De Raffele E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8: 10.
34. Barría MI, Vera-Otarola J, León U, et al. Influence of extrahepatic viral infection on the natural history of hepatitis C. Ann Hepatol 2008; 7: 136.
35. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. Hepatology 2006; 44: 15.
36. Radkowski M,Wang LF, Vargas HE, et al. Detectionof hepatitisC virus replicationin peripheral blood mononuclear cells after orthotopic liver transplantation. Transplantation 1998; 66: 664.
37. Di Martino V, Brenot C, Samuel D, et al. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apo-ptosis after liver transplantation for hepatitis C. Transplantation 2000; 70: 1390.
38. Hsu EC, Hsi B, Hirota-Tsuchihara M, et al. Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol 2003; 21: 519.
39. Delladetsima I, Psichogiou M, Alexandrou P, et al. Apoptosis and hepatitis C virus infection in renal transplant recipients. Am J Clin Pathol 2008; 129: 744.
40. Drognitz O, Obermaier R, Liu X, et al. Effects of organ preservation, ischemia time and caspase inhibition on apoptosis and microcircu-lation in rat pancreas transplantation. Am J Transplant 2004; 4: 1042.
41. Song SW, Guo KJ, Shi R, et al. Pretreatment with calcitonin gene-related peptide attenuates hepatic ischemia/reperfusion injury in rats. Transplant Proc 2009; 41: 1493.
42. Bottinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27: 309.
43. Tyler JR, Robertson H, Booth TA, et al. Chronic allograft nephrop-athy: Intraepithelial signals generated by transforming growth factor-beta and bone morphogenetic protein-7. Am J Transplant 2006; 6: 1367.
44. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600.
45. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: Open software development for computational biology and bioinformat-ics. Genome Biol 2004; 5: R80.
46. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing 2005.
47. Mas VR, Archer KJ, Yanek K, et al. Gene expression patterns in deceased donor kidneys developing delayed graft function after kidney transplantation. Transplantation 2008; 85: 626.
48. Maluf DG, Mas VR, Archer KJ, et al. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibro-sis. Mol Med 2008; 14: 276.
49. Irizarry RA, Hobbs B, Collin F, et al. Exploration, 21normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249.
50. Gautier L, Cope L, Bolstad BM, et al. Affy-Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307.
51. Archer KJ, Dumur CI, Joel SE, et al. Assessing quality of hybridized RNA in Affymetrix GeneChip experiments using mixed effects models. Biostatistics 2006; 7: 198.
52. Archer K. An application for assessing quality of RNA hybridized to Affymetrix GeneChips. Bioinformatics 2006; 22: 2699.